BGNE:NSD-BeiGene, Ltd (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 282.40

Change

0.00 (0.00)%

Market Cap

USD 24.87B

Volume

0.25M

Average Target Price

USD 225.43 (-20.17%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People's Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R/R mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; KYPROLIS to treat multiple myeloma; BLINCYTO to treat acute lymphocytic leukemia; SYLVANT to treat idiopathic multicentric castleman disease; and QARZIBA to treat neuroblastoma. The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Pamiparib, an inhibitor of PARP1 and PARP2 to treat various solid tumors; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumor. In addition, its clinical stage drug candidates include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; BGB-A1217, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; and BGB-A445, an OX40 agonist antibody to treat solid tumors. The company has collaborations with Celgene Corporation; Merck KGaA; Mirati Therapeutics, Inc.; BioAtla, LLC; Zymeworks, Inc.; Ambrx, Inc.; Atreca Inc.; IGM Biosciences, Inc.; and Hutchison China MediTech Limited. BeiGene, Ltd. was founded in 2010 and is based in Beijing, the People's Republic of China.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD69.85B 33.27 26.59
REGN Regeneron Pharmaceuticals, Inc

N/A

USD61.08B 21.61 16.69
SGEN Seattle Genetics, Inc

N/A

USD32.18B N/A N/A
MRNA Moderna, Inc

N/A

USD27.41B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

USD25.08B 29.87 27.00
RPRX Royalty Pharma plc

N/A

USD24.33B 36.15 9.83
GMAB Genmab A/S

N/A

USD23.46B 28.02 3.06
IMMU Immunomedics, Inc

N/A

USD19.73B N/A N/A
INCY Incyte Corporation

N/A

USD18.93B 47.64 35.20
ALNY Alnylam Pharmaceuticals, Inc

N/A

USD16.04B N/A N/A

ETFs Containing BGNE

Symbol Name Weight Mer Price(Change) Market Cap
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

N/A

USD0.03B
CNCR Loncar Cancer Immunothera.. 0.00 % 0.79 %

N/A

USD0.04B
CHNA Loncar China BioPharma ET.. 0.00 % 0.79 %

N/A

USD0.01B
CHNA Loncar China BioPharma ET.. 0.00 % 0.79 %

N/A

USD0.01B
GDNA Goldman Sachs Human Evolu.. 0.00 % 0.50 %

N/A

USD0.03B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 70.37% 84% B 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.37% 84% B 89% B+
Trailing 12 Months  
Capital Gain 132.26% 85% B 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 132.26% 85% B 92% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 81.20% N/A N/A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 81.20% N/A N/A 96% A
Risk Return Profile  
Volatility (Standard Deviation) 110.38% N/A N/A 8% F
Risk Adjusted Return 73.56% N/A N/A 84% B
Market Capitalization 24.87B 99% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 9.86 17% F 12% F
Price / Cash Flow Ratio -33.14 88% B+ 91% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -67.89% 49% F 19% F
Return on Invested Capital -61.58% 52% F 16% F
Return on Assets -29.59% 45% F 13% F
Debt to Equity Ratio 25.01% 46% F 59% F
Technical Ratios  
Short Ratio 10.51 20% F 12% F
Short Percent N/A N/A N/A N/A N/A
Beta 1.31 59% F 37% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector